ICU Medical, Inc.

As of June 30, 2026, ICU Medical, Inc. carries a market capitalization of 3.20B, placing it among publicly traded companies globally. Its enterprise value stands at 4.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

ICU Medical, Inc.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, ICU Medical, Inc. has 25.01M shares outstanding.

As of June 30, 2026, ICU Medical, Inc. trades at a trailing price-to-earnings ratio of 120.45. The price-to-sales ratio is 1.68, and the price-to-book ratio stands at 1.70.

As of June 30, 2026, ICU Medical, Inc. trades at an EV/EBITDA multiple of 16.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 64.25 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.05B versus a market cap of 3.20B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ICU Medical, Inc. maintains a current ratio of 2.43, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 59.09, indicating elevated leverage, while an interest coverage ratio of 3.33 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ICU Medical, Inc. posted a return on equity (ROE) of 1.41, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.74, measuring how efficiently the asset base is converted into earnings. The company generates approximately 140,022.19 in revenue per employee across its workforce of 13,500.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.15 indicates how many times ICU Medical, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ICU Medical, Inc. recorded an income tax benefit of -27.09M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 659,976.20, leaving 26.34M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ICU Medical, Inc.'s stock has gained approximately 42.86% over the past 52 weeks. The 50-day moving average sits at 145.30, while the 200-day moving average is 128.41.

Over the twelve months ended June 30, 2026, ICU Medical, Inc. generated 1.89B in revenue and converted that into 26.34M in net income, yielding earnings per share of 1.06. EBITDA reached 239.25M, while operating income came in at 125.83M.

As of June 30, 2026, ICU Medical, Inc. holds 261.10M in cash and equivalents against 1.11B in total debt, resulting in a net debt position of 816.57M. Total book value stands at 1.88B, with working capital of 623.69M providing operational flexibility.

ICU Medical, Inc. produced 206.89M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -80.11M in capital expenditures, free cash flow totaled 126.78M - equivalent to 5.12 per share.

Over the twelve months ended June 30, 2026, ICU Medical, Inc. posted a gross margin of 39.13, reflecting its pricing power and cost economics. The operating margin of 6.66 and net profit margin of 1.39 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 3.98, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.23, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ICU Medical, Inc. shareholders.

ICU Medical, Inc.'s most recent stock split took place on March 18, 2002 with a 2:3 split ratio.

As of June 30, 2026, ICU Medical, Inc. has an Altman Z-Score of 3.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.